Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
AbCellera Biologics Inc. (ABCL) had Return on Tangible Equity of -4.88% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$4.24M |
|
$-45.62M |
|
-- |
|
$4.24M |
|
$66.89M |
|
$-62.66M |
|
$9.68M |
|
$-52.98M |
|
$-52.98M |
|
$-45.62M |
|
$-45.62M |
|
$-45.62M |
|
$-45.62M |
|
$-62.66M |
|
$-56.05M |
|
297.69M |
|
297.69M |
|
$-0.15 |
|
$-0.15 |
|
| Balance Sheet Financials | |
$764.98M |
|
$347.10M |
|
$579.23M |
|
$1.34B |
|
$75.40M |
|
-- |
|
$245.83M |
|
$321.23M |
|
$1.02B |
|
$933.98M |
|
$1.02B |
|
298.36M |
|
| Cash Flow Statement Financials | |
$-11.55M |
|
$7.93M |
|
$5.97M |
|
$183.62M |
|
$186.56M |
|
$2.94M |
|
$14.79M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.15 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1479.58% |
|
-1479.58% |
|
-- |
|
-1251.10% |
|
-1077.24% |
|
$-22.19M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
0.11 |
|
850.17 |
|
-4.46% |
|
|
Return on Tangible Equity |
-4.88% |
-3.39% |
|
-4.46% |
|
$3.43 |
|
$-0.07 |
|
$-0.04 |
|